tiprankstipranks
Trending News
More News >

Simcere’s ENZESHU® Gains Approval in China for Platinum-Resistant Ovarian Cancer

Story Highlights
  • Simcere’s ENZESHU® approved in China for treating platinum-resistant ovarian cancer.
  • ENZESHU® offers new therapeutic option, showing significant efficacy in clinical trials.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Simcere’s ENZESHU® Gains Approval in China for Platinum-Resistant Ovarian Cancer

Don’t Miss TipRanks’ Half-Year Sale

Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an announcement.

Simcere Pharmaceutical Group Limited announced the approval of ENZESHU® (Suvemcitug for injection) for marketing in China by the National Medical Products Administration. This new biological drug, developed in collaboration with Pyxis Oncology, Inc., is designed to treat recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with platinum-resistant ovarian cancer. ENZESHU® is the first anti-angiogenic therapy approved in China for this condition, offering a new therapeutic option for patients. The drug demonstrated significant efficacy in clinical trials, extending progression-free survival and overall survival, marking a significant advancement in treatment options for these patients.

More about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. It focuses on developing innovative drugs, particularly in the field of oncology, and has a market focus on addressing unmet clinical needs in China.

Average Trading Volume: 16,082,642

Technical Sentiment Signal: Buy

Current Market Cap: HK$27.52B

For an in-depth examination of 2096 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1